Hypogonadism due to therapy with GnRH agonists in men with prostate cancer is associated with increased fat mass [25, 26], whereas testosterone treatment in hypogonadism results in improved insulin sensitivity and decreased fat mass in patients with type 2 diabetes mellitus [27]. This evidence concerns the gene INS and prostate carcinoma.